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Preamble
The year 2014 has become a remarkable year for heart failure. A bad
start was caused by the publication of TOPCAT, showing that spir-
onolactone did not prove to be beneficial for the treatment of
patients with heart failure and preserved ejection fraction (HFpEF).
Nevertheless, further insights in the study yields a few bright spots,
and treatment with spironolactone might still be considered in
patients with HFpEF. In acute heart failure, additional data were pub-
lishedon the effects of serelaxin. Serelaxin reducedwedgepressures,
had similar effects in acute heart failure patients with and without a
reduced ejection fraction, and had a neutral effect on diuretic re-
sponse. But the most important news was related to the results of
PARADIGM, where LCZ696, the first-in-class angiotensin-receptor
neprilysin inhibitor, proved to be superior to enalapril in reducing
mortality and morbidity in patients with heart failure and reduced
ejection fraction (HFrEF).
ACE inhibitors in heart failure
with reduced ejection fraction:
the end of an era?
During the last decades, treatment of patients with heart failurewith
reducedejection fraction (HFrEF)has improveddramaticallywith the
introduction of ACE-inhibitors, b-blockers, angiotensin receptor
blockers, and mineralocorticoid receptor antagonists. This caused
a stepwise reduction in mortality and heart failure hospitalization.
However, residualmortality andmorbidity is still toohigh. Therefore,
there is a continuous need for better therapies.
The biggest heart failure newsof 2014 in heart failurewas the pres-
entation and publication of the PARADIGM trial.1 The trial reported
the effects of LCZ696, a first in class angiotensin receptor neprilysin
inhibitor. LCZ696 comprises themolecularmoieties of the angioten-
sin II AT1 receptor antagonist valsartan and the neprilysin inhibitor
prodrug AHU377.2 In PARADIGM, the effect of LCZ696 on a com-
posite of death from cardiovascular causes or hospitalization for
heart failure was compared with enalapril in 8442 patients with
HFrEF. The trial was stopped prematurely due to an overwhelming
benefit of LCZ696. Compared with enalapril, LCZ696 significantly
reduced the primary endpoint by 20% and all-cause mortality by
16%. The drug was well tolerated, with no increase in angioedema,
which was a concern with the combined ACE-inhibitor/neprilysin
inhibitor omapatrilat. There were more cases of symptomatic hypo-
tension in the LCZ696 group and less cases of worsening of renal
function. The major question is to which extent should LCZ696
replace ACE inhibitors in patients with HFrEF, for whom these
agents are a mainstay. Although the trial was well conducted, the
run-in period is of concern. More than 1200 patients were excluded
because of adverse events or abnormal laboratory test results. So,
patients who tolerated enalapril but became hypotensive on
LCZ696 in the second run-in phase were not included in this study,
which might have biased the results in favour of LCZ696. Neverthe-
less, since the CONSENSUS trial was published in 1987, this is the
first drug that proved to be superior over enalapril, and therefore
this trial will probably be the end of an era. The drug now needs to
be approved and reimbursed, so it will unfortunately take some
time before the drug will be readily available, but this will provide
physicians and policy-makers time to get more insights in the study.
The second important trial that was presented and published
during the scientific sessions of the European Society of Cardiology
in Barcelona, September 2014, was the CONFIRM-HF trial.3 This
trial confirmed beneficial effects of intravenous iron on symptoms,
functional capacity, and quality of life in patients with HFrEF, with
and without anaemia. Iron deficiency (ferritin level ,100 mg per L
or between 100 and 299 mg per L, if the transferrin saturation is
,20%) is found in .40% of patients with HFrEF, and is related to
severity of symptoms and a poor clinical outcome. CONFIRM-HF
was a double-blind, placebo-controlled trial in 304 HFrEF patients
with iron deficiency. Patients were randomized 1 : 1 to treatment
with i.v. iron, as ferric carboxymaltose or placebo for 52 weeks.
Ferric carboxymaltose improved functional capacity, symptoms,
and quality of life and was associated with a reduction in the risk of
hospitalization for worsening heart failure (Figure 1). CONFIRM-HF
confirmed the results of FAIR-HF that were nearly identical.4
However, blinding of these patients in both studies remained difficult,
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which is important due to the soft endpoints that were used. Also,
both FAIR-HF and CONFIRM-HF were too small to show effects
(both beneficial and/or deleterious) on mortality.
A third study that received a lot of attention in 2014was related to
the efficacy of b-blockers in patients with HFrEF and atrial fibrilla-
tion.5 A pooled analysis was performed using individual patient data
from 10 randomized controlled trials that compared b-blockers
and placebo in HFrEF. Overall, 18 254 patients were included
(13 946 in sinus rhythm and 3066 with atrial fibrillation). b-Blockers
were associated with a 27% reduction in all-cause death among
HFrEF patients in sinus rhythm, but among patients with AF, nomor-
tality reduction was seen. The authors conclude that b-blockers
should not be regarded as standard therapy to improve prognosis
in patients with concomitant heart failure and atrial fibrillation.
However, we have to be careful with sub-group analyses, even
when performed in such a well-performed meta-analysis, and
prospective studies in HFrEF patients with AF should be performed
to establish the value of b-blockers in HFrEF patients with atrial
fibrillation.
Finally, in May 2014, long-term follow-up data of the MADIT-
cardiac resynchronization therapy (CRT) trial were published in
the New England Journal of Medicine.6 The original study enrolled
1820 patients to either CRT-D or ICD in patients with mild HFrEF
(NYHA classes I– II; LVEF ≤30%) and a QRS duration of 130 ms or
more. After a follow-up of 2.4 years, CRT-D was associated with
a significant reduction in death from any cause or a heart-failure
event. However, the outcome was mainly driven by heart-failure
events. After a median follow-up of 5.6 years, a 41%mortality reduc-
tion was shown in patients with left bundle branch block, while no
benefit was found in patients without a left bundle branch block.
Figure 1 Patient global assessment and NYHA functional class over time (full-analysis set). The data presented are odds ratios for patient global
assessment (A) andNYHA functional class (B) for the ferric carboxymaltose groupwhen comparedwith the placebo, of being in a better categoryof
patient global assessment (A) andNYHA functional class (B). In those panels, the P-values are for the comparison between the two study groups, and
the I bars denote the 95% confidence intervals.
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A better understanding to improve
treatment of heart failure and
preserved ejection fraction
The biggest disappointment of 2014 was the results of TOPCAT.7
TOPCAT failed to show a beneficial effect of spironolactone on the
primary composite endpoint of cardiovascular death or hospital admis-
sion for heart failure in 3445 patients with heart failure and preserved
ejection fraction (HFpEF). After ACE-inhibitors and angiotensin recep-
tor blockers, this is the third group of blockers of the renin–angioten-
sin–aldosterone system (RAAS) that failed in HFpEF patients, but
previously showed a beneficial effect in patients with HFrEF.
However, a few important issues need to be taken into account. First,
spironolactone significantly reduced hospital admissions for heart
failure, but increased the risk on worsening of renal function (doubling
of serum creatinine) and hyperkalemia.7 Therefore, there might be
some benefit with the use of spironolactone in patients with HFpEF,
but patients always need to be carefully controlled for renal function
and potassium. Second, there was a remarkable difference between
patients that were recruited in Russia and Georgia, compared with
patients that were recruited in North America. Patients in Russia and
Georgia had a much lower event rate, and spironolactone was not
beneficial in these patients. In contrast, spironolactone significantly re-
duced the primary endpoint in patients that were recruited in North
America. Taken together, there is no strong evidence in favour of the
use of mineralocortocoid receptor antagonists in patients with HFpEF.
After the dust had descended, themost striking question was how
RAAS inhibitors can be so successful in HFrEF, yet fail to show a
benefit inHFpEF? First, due to the complicateddiagnosis, recruitment
of patients inHFpEF studies is oftenmoredifficult thanHFrEF studies.
If the inclusion criteria are too lenient, patients with other causes of
their complaints instead of HFpEF might be included and dilute the
effects of the drug. If the criteria are too strict, it will bemore difficult
to recruit patients, and the studywill takemuch longer thanexpected,
aswas the casewith TOPCAT.A longer duration of the trial is related
to a high crossover and dropout rate, further diluting the effects of
the drug. But thirdly, it starts to become clear that HFpEF is different
fromHFrEF, and drugs that are effective in HFrEF are not necessarily
effective in HFpEF. Therefore, a better understanding of the patho-
physiology of the disease is highly needed. In 2014, studies were
published that attempted to better phenotype HFpEF patients.
Two recent studies showed that coronary artery disease is
common in patients with HFpEF and is associated with increased
mortality and greater deterioration in ventricular function.8,9 The
authors assumed that revascularizationmay be associated with pres-
ervation of cardiac function and improved outcomes in HFpEF
patients with coronary artery disease. Another important finding in
patients with HFpEF is the observation that they have greater mech-
anical dyssynchrony compared with healthy controls of similar age
and gender.10 Within the HFpEF population, the severity of dyssyn-
chrony was related to the width of QRS complex, LV hypertrophy,
and diastolic dysfunction. These data might pave the way to studying
the effects of CRT in patients with HFpEF. In summary, a better char-
acterization of different phenotypes of HFpEF patients will likely
improve our understanding and might lead to better and more
tailored therapies in HFpEF.
Technology in heart failure:
implant-based multiparameter
telemonitoring and chronic vagal
stimulation
Novel technologies are increasingly used in the diagnosis and treat-
ment of patients with heart failure, but uncertainty remains on the
effects on clinical outcome. In the 2012ESCHeart FailureGuidelines,
a distinction ismadebetween remotemonitoringwithorwithout the
use of an implanted device.11 Data both on non-invasive and invasive
remote monitoring are inconsistent and do not yet support a guide-
line recommendation. Recently, data were published on a rando-
mized clinical trial on the effect of telemonitoring using data from
a recently implanted ICD or CRT-D12 in 664 HFrEF patients. The
primary outcomemeasurewas a composite clinical score combining
all-cause death, overnight hospital admission for heart failure, change
in NYHA class, and change in patient global self-assessment. After
1 year, 63 (18.9%) of 333 patients in the telemonitoring group vs.
90 (27.2%) of 331 in the control group (P ¼ 0.013) had worsened
composite score (odds ratio: 0.63, 95%CI: 0.43–0.90). Since patients
with HFrEF often receive an ICD or CRT-D anyway, the current
approach is feasible and might improve clinical outcome. The only
downside is the amount of data that is transferred and needs to be
monitored and the decision-making process and protocols used to
streamline these data.
Another technology that is increasingly studied in heart failure is
the use of direct vagal nerve stimulation to enhance parasympathetic
tone (Figure 2). In September 2014, data of the first randomized
sham controlled trial on direct vagal nerve stimulation were
Figure2 (A) Investigational bipolar helical vagal cuff. (B) Precision
(TM) Pulse Generator and implanted lead.
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presented and published.13 After 6 months of treatment, there was
no difference in the primary endpoint of change in left ventricular
end systolic diameter between patients with the device ON or
OFF.However, patientswith the deviceONexperienced statistically
significant improvements in symptoms and quality of life, which were
secondary endpoints of the trial. However, these are soft-endpoints
that might be affected by subjective feelings of being treated, rather
than to a direct beneficial cardiac effect of the device. In addition,
blinding in the NECTAR-HF trial might be confounded since inter-
vention in the ON group is expected to decrease heart rate. Never-
theless, results from similar studies are expected in the upcoming
years.
More data on serelaxin in acute
heart failure
Serelaxin is a vasoactive peptide hormone with vasodilatory, anti-
fibrotic, anti-inflammatory, and pro-angiogenic effects that is cur-
rently under investigation for the treatment of patients with acute
decompensated heart failure. RELAX-AHF demonstrated beneficial
effects on relief of dyspnoea and (cardiovascular) mortality, but not
on heart failure readmissions in 1161 patients with acute heart
failure.4 The large RELAX-AHF2 trial, that aims to include 6375
patients with acute heart failure, and with cardiovascular mortality
as the primary endpoint, is currently ongoing. In the meantime,
more data on serelaxin were published in 2014. First, a randomized,
double-blind, placebo-controlled, multicentre study assessed the
haemodynamic effects of serelaxin in 63 patients with acute heart
failure.15 Serelaxin significantly decreased pulmonary capillary wedge
pressure during the first 8 h of infusion, but showed no significant
effect on the peak change in cardiac index vs. placebo (Figure 3).
Another sub-group analysis of theRELAX-AHF trial showed that ser-
elaxin had similar effects in acute heart-failure patients with a pre-
served and a reduced left ventricular ejection fraction.16 Finally,
another publication showed that serelaxin was associated with less
diuretic use, but also with less net weight loss, and therefore had a
neutral effect on diuretic response.17
The future of heart failure:
epigenetics?
Anumber of interesting novel developments related to (epi)genetics
are ongoing in heart failure. One example is the intracoronary infu-
sion of AAV1/ sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a)
gene transfer in patients with severe heart failure. In HF, the level
and the activity of SERCA2a is decreased, contributing directly to
impaired cardiac contraction and relaxation. Recently, long-term
follow-up data were published of the CUPID trial, a phase II rando-
mized, double-blind, placebo-controlled study on the effects of
AAV1/SERCA2a vs. placebo in 39 patients with advanced HF.18
After 3 years of follow-up, the risk of pre-specified recurrent cardio-
vascular events (myocardial infarction, worsening heart failure,
heart-failure-related hospitalization, ventricular assist device place-
ment, cardiac transplantation, and death) was reduced by 82% in
the high-dose vs. placebo group (P ¼ 0.048). No safety concerns
were noted during the 3-year follow-up.
A second example is the increasing interest in the role of mircoR-
NAs in heart failure. MircoRNAs are small non-coding RNAs
that regulate gene-transcription and protein formation. Wahlquist
et al. aimed to identify miRNAs that suppress intracellular calcium
handling in heart muscle by interacting with messenger RNA encod-
ing the sarcoplasmic reticulum calcium uptake pump SERCA2a.18
MicroNA-25 potently delayed calcium uptake kinetics in cardiomyo-
cytes in vitro and was upregulated in heart failure. Interestingly, injec-
tion of an antisense oligonucleotide (antagomiR) against miR-25
markedly halted established heart failure in a mouse model.19
Conclusions
Overall, 2014 has become a good year for our heart failure patients.
Further improvement in the treatment ofHFrEF can be achievedwith
LCZ696 and intravenous iron. Pharmacological treatment of HFpEF
remains problematic, especially after the neutral results of TOPCAT
with spironolactone. A better characterization of the patients and a
better pathophysiological insight are strongly needed to improve
the outcome of patients with HFpEF. In acute heart failure, recent
results from RELAX-AHF have resulted in a renewed interest from
researchers and industry to further improve outcome of this
deadly syndrome.
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